(Q44760892)

English

Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials

scientific article published on 13 March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 December 2017

Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials (English)

1 reference

Europe PubMed Central

6 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

atrial fibrillation

1 reference

based on heuristic

inferred from title

author name string

John G F Cleland

1

1 reference

Europe PubMed Central

6 December 2017

Rhiddian Shelton

2

1 reference

Europe PubMed Central

6 December 2017

Nikolay Nikitin

3

1 reference

Europe PubMed Central

6 December 2017

Sarah Ford

4

1 reference

Europe PubMed Central

6 December 2017

Lars Frison

5

1 reference

Europe PubMed Central

6 December 2017

Margaretha Grind

6

1 reference

Europe PubMed Central

6 December 2017

publication date

13 March 2007

1 reference

Europe PubMed Central

6 December 2017

European Journal of Heart Failure

1 reference

Europe PubMed Central

6 December 2017

9

1 reference

Europe PubMed Central

6 December 2017

730-739

1 reference

Europe PubMed Central

6 December 2017

6-7

1 reference

Europe PubMed Central

6 December 2017

Systematic review of the management of atrial fibrillation in patients with heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) pro

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Are hematinic deficiencies the cause of anemia in chronic heart failure?

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Prevention of and medical therapy for atrial arrhythmias in heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Is aspirin safe for patients with heart failure?

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.01.013

21 January 2018

Identifiers

10.1016/J.EJHEART.2007.01.013

1 reference

Europe PubMed Central

6 December 2017

1 reference

Europe PubMed Central

6 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44760892&oldid=2039426194"